CR8650A - DERIVADOS DE IMIDAZOL USADOS COMO INHIBIDORES DE TAFIa - Google Patents

DERIVADOS DE IMIDAZOL USADOS COMO INHIBIDORES DE TAFIa

Info

Publication number
CR8650A
CR8650A CR8650A CR8650A CR8650A CR 8650 A CR8650 A CR 8650A CR 8650 A CR8650 A CR 8650A CR 8650 A CR8650 A CR 8650A CR 8650 A CR8650 A CR 8650A
Authority
CR
Costa Rica
Prior art keywords
derivatives used
tafia inhibitors
imidazol derivatives
inhibitors
compounds
Prior art date
Application number
CR8650A
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8650(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR8650A publication Critical patent/CR8650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a compuestos de formula (I) que son inhibidores del inhibidor de la fibrinolisis activable por trombina activado. Los compuestos de formula (I) resultan adecuados para producir medicamentos para la profilaxis y el tratamiento de enfermedades acompanadas de trombosis, embolismos, hipercoagulabilidad o cambios fibroticos.
CR8650A 2004-04-22 2006-09-22 DERIVADOS DE IMIDAZOL USADOS COMO INHIBIDORES DE TAFIa CR8650A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
CR8650A true CR8650A (es) 2007-12-04

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8650A CR8650A (es) 2004-04-22 2006-09-22 DERIVADOS DE IMIDAZOL USADOS COMO INHIBIDORES DE TAFIa

Country Status (35)

Country Link
EP (2) EP1864979B1 (es)
JP (1) JP4939401B2 (es)
KR (1) KR101162047B1 (es)
CN (1) CN100572376C (es)
AR (1) AR053302A1 (es)
AT (2) ATE523505T1 (es)
AU (1) AU2005238144B2 (es)
BR (1) BRPI0510159A (es)
CA (1) CA2563401C (es)
CR (1) CR8650A (es)
CY (1) CY1108087T1 (es)
DE (2) DE102004020186A1 (es)
DK (1) DK1740569T3 (es)
EC (1) ECSP066941A (es)
ES (1) ES2299026T3 (es)
HK (1) HK1101823A1 (es)
HR (1) HRP20080099T3 (es)
IL (1) IL178672A (es)
MA (1) MA28543B1 (es)
MY (1) MY140903A (es)
NI (1) NI200600217A (es)
NO (1) NO20065320L (es)
NZ (1) NZ550757A (es)
PE (1) PE20060172A1 (es)
PL (1) PL1740569T3 (es)
PT (1) PT1740569E (es)
RS (1) RS50553B (es)
RU (1) RU2375356C2 (es)
SI (1) SI1740569T1 (es)
TN (1) TNSN06341A1 (es)
TW (1) TWI359016B (es)
UA (1) UA87306C2 (es)
UY (1) UY28868A1 (es)
WO (1) WO2005105781A1 (es)
ZA (1) ZA200607668B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553219B (zh) * 2006-12-06 2013-04-24 塞诺菲-安万特股份有限公司 作为TAFIa抑制剂的脲和磺酰胺衍生物
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8470863B2 (en) * 2007-02-13 2013-06-25 Merck Sharp & Dohme, Corp. Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists
BRPI0814294A2 (pt) 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
NZ589671A (en) 2008-06-06 2012-03-30 Sanofi Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
SG176558A1 (en) * 2009-05-15 2012-01-30 Sanofi Sa Process for the preparation of a compound useful as an inhibitor of tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
JP5807006B2 (ja) 2010-03-18 2015-11-10 第一三共株式会社 シクロアルキル基で置換されたイミダゾール誘導体
MX2013004193A (es) * 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
US9834527B2 (en) * 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
CN108883094A (zh) 2016-03-29 2018-11-23 第三共株式会社 炎症性肠病治疗剂
KR20190035752A (ko) 2016-08-03 2019-04-03 사이머베이 쎄라퓨틱스, 인코퍼레이티드 염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
ATE523505T1 (de) 2011-09-15
NZ550757A (en) 2010-06-25
KR101162047B1 (ko) 2012-07-04
AU2005238144B2 (en) 2010-08-26
IL178672A (en) 2011-08-31
CN1950357A (zh) 2007-04-18
JP4939401B2 (ja) 2012-05-23
UA87306C2 (en) 2009-07-10
NO20065320L (no) 2007-01-12
JP2007533672A (ja) 2007-11-22
EP1740569A1 (de) 2007-01-10
ES2299026T3 (es) 2008-05-16
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
RU2375356C2 (ru) 2009-12-10
CY1108087T1 (el) 2014-02-12
SI1740569T1 (sl) 2008-06-30
DE502005002927D1 (de) 2008-04-03
TW200602325A (en) 2006-01-16
EP1864979A1 (de) 2007-12-12
BRPI0510159A (pt) 2007-10-02
AU2005238144A1 (en) 2005-11-10
AR053302A1 (es) 2007-05-02
WO2005105781A1 (de) 2005-11-10
PL1740569T3 (pl) 2008-07-31
DK1740569T3 (da) 2008-06-02
CA2563401C (en) 2012-08-07
HRP20080099T3 (en) 2008-03-31
MA28543B1 (fr) 2007-04-03
NI200600217A (es) 2008-06-17
MY140903A (en) 2010-01-29
PE20060172A1 (es) 2006-03-31
ZA200607668B (en) 2008-03-26
HK1101823A1 (en) 2007-10-26
EP1864979B1 (de) 2011-09-07
DE102004020186A1 (de) 2005-11-17
ATE386737T1 (de) 2008-03-15
TWI359016B (en) 2012-03-01
TNSN06341A1 (en) 2008-02-22
EP1740569B1 (de) 2008-02-20
RS50553B (sr) 2010-05-07
RU2006141246A (ru) 2008-06-10
UY28868A1 (es) 2005-11-30
IL178672A0 (en) 2007-02-11
CN100572376C (zh) 2009-12-23
PT1740569E (pt) 2008-03-31
KR20070007346A (ko) 2007-01-15

Similar Documents

Publication Publication Date Title
CR8650A (es) DERIVADOS DE IMIDAZOL USADOS COMO INHIBIDORES DE TAFIa
DOP2010000363A (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia
UY30600A1 (es) Compuestos novedosos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
SV2011003855A (es) Heteroarilos sustituidos
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
ECSP066717A (es) Compuestos de quinolina sustituidos
UY29549A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
CL2020003331A1 (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
PE20151248A1 (es) Derivados de ciclopentano como inhibidores de catepsinas
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
DOP2007000142A (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
PA8768201A1 (es) Composiciones farmacéuticas que contienen derivados de ácido indol sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1)
CU23955B1 (es) PIRIMIDINAS BICÍCLICAS FUSIONADAS COMO INHIBIDORES EFECTIVOS DE LA VÍA Pi3K/Akt